Methylation & Proteomics-Based Detection of Bladder Cancer
- Abbreviated Name
- BLADDER-PRE-VAL
- Lead Investigator
- Cairns, Paul — Fox Chase Cancer Center
- Coordinating Investigator
- Feng, Ziding — Fred Hutchinson Cancer Center
- Involved Investigators
-
- Feng, Ziding — Fred Hutchinson Cancer Center
- Kibel, Adam — Brigham and Womens Hospital
- Wei, John — University of Michigan Recruiting
- Wagner, Andrew — Beth Israel Deaconess Medical Center
- Sidransky, David — Johns Hopkins University
- Leach, Robin J — University of Texas Health Science Center at San Antonio
- Srivastava, Sudhir — National Cancer Institute
- Sanda, Martin — Emory University
- Czerniak, Bogdan — The University of Texas MD Anderson Cancer Center
- Schoenberg, Mark P. — Johns Hopkins University
- Cairns, Paul — Fox Chase Cancer Center
Abstact
Study never Launched
Aims
This study will test the sensitivity of gene methylation in the presence of clinically evident, pathologically confirmed bladder cancer. This study will test the specificity of gene methylation in two groups of participants without bladder cancer - requiring cystoscopy for hematuria and for foreign body (urinary stones, stents, and catheters) or infection.
Analytic Method
Quantitative real time methylation specific PCR (qMSP) of urine sediment DNA using a panel of several methylated gene markers.
Biomarkers
- No biomarkers available at this time for this protocol
Data Collections
- No data available at this time for this protocol
- Protocol ID
- 226
- Protocol Type
- Collaboration
- Field of Research
- Hypermethylation
- Collaborative Group
- Prostate and Urologic Cancers Research Group
- Cancer Types
-
- Malignant neoplasm of bladder
- Phased Status
- 1